To the Editor: I am writing in response to the recent article by Harvey and colleagues about complementary medicines in Australia.1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Business Development and Regulatory Affairs Department, Rottapharm SpA, Monza, Italy.
Correspondence: antonino.santoro@rottapharm.com
- 1. Harvey KJ, Korczak VS, Marron LJ, Newgreen DB. Commercialism, choice and consumer protection: regulation of complementary medicines in Australia. Med J Aust 2008; 188: 21-25. <MJA full text>
- 2. Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007; 56: 2105-2110.
- 3. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-256.
- 4. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56: 555-567.
- 5. Altman RD, Abramson S, Bruyere O, et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage 2006; 14: 963-966.
- 6. Vlad SC, LaValley MP, McAlindon TE, et al. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007; 56: 2267-2277.
Online responses are no longer available. Please refer to our instructions for authors page for more information.